Empowering Oncologists.
Today.

Microtumor testing achieves a new level.
How does it empower the oncologist?

This is how IndiTreat works

Predicting tumor resistance and sensitivity

Until today, there have been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first-line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance*, causing a measurable burden on clinic resources and immeasurable patient suffering.

Over the last decade, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes testing on patient-derived microtumors an operational reality to serve you and your clinic.

* European Journal of Cancer 81 (2017) 191–202

Interested in a free IndiTreat® test?

What does this mean for you the oncologist and your patients?

Predict tumor resistance and sensitivity to cancer drugs
Select the most appropriate treatment, in accordance with guidelines or off-label
Improve patient quality of life through in vitro testing of drug efficacy on the individual patient

IndiTreat® for cancer therapy selection

With IndiTreat®, you can test different panels of drugs and drug combinations on microtumors derived from individual patients to identify resistance and sensitivity.

IndiTreat® Colorectal Cancer Test

A method of determining which drugs offer the most suitable therapies for different patients with stage IIIIV colorectal cancer, this test can be used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy
  • 1st and 2nd line therapy of metastatic disease
  • Therapy of end-stage metastatic patients
  • HIPEC (hyperthermic intraperitoneal chemotherapy)

IndiTreat® Ovarian Cancer Test

This test indicates which panels offer the most suitable therapies for different patients with ovarian cancer. This test is used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy
  • Therapy of recurrence regardless of previous platinum response
  • Selection of the most effective PARP-inhibitor in BRCA-mt patients
  • Selection of BRCA-wt patients who shall benefit from PARP-inhibition
  • Therapy of end-stage patients

IndiTreat® Pancreatic Cancer Test

A method of determining which drugs offer the most suitable therapies for different patients with pancreatic cancer. This test is used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy if a pancreatic biopsy is feasible
  • 1st and 2nd line palliative therapy

Predict tumor resistance and sensitivity to treatment

IndiTreat® uses thousands of patient-derived microtumors to evaluate the response of your patients’ tumors to drugs and drug combinations. These include drugs recommended by guidelines and as a special request, we can test off label. We are able to recommend drugs as well as drug combinations. Drug combinations are of particular significance to IndiTreat®, as IndiTreat® is today the only practical means to test the effect of different combinations.

Interested in a free IndiTreat® test?

IndiTreat® is ready for your patients today

IndiTreat® tests are performed at 2cureX laboratories in Europe. Now we can perform tests on your patients and can compare to results from reference patients.

Drug sensitivity testing on patient-derived 3D microtumors can provide vital information for every individual patient, and improve the likelihood of success of cancer treatment. IndiTreat® is a useful complement to the advances achieved in individual patient genomic characterization of tumors.

Learn more about IndiTreat®

Listen to 2cureX CMO Dr. Henrik Harling discussing the dilemma facing the oncologist on the choice of first line colorectal cancer treatment.
Listen to 2cureX CBO Maarten van der Linden talking about availability and application of IndiTreat® Sensitivity Test for colorectal, pancreatic and ovarian cancer patients.

Improving the likelihood of success of cancer treatment

2cureX, pioneers in the use of 3D microtumors in cancer therapy, empowering oncologists to select treatments more efficiently and thereby improve treatment outcomes.

Interested in a free IndiTreat® test?

To find out more, talk to 2cureX

Whether you want to try the IndiTreat® IVD test on a patient or complement your genomic tumor characterisation with functional data on resistance and sensitivity to drugs, we are here to support you.

Phone: +45 2211 5399 | E-mail: info@2curex.com

Or, tell us when you're free:

Book an online meeting

Register your interest and join the drawing to win a free test.

Win a free IndiTreat® test for one of your colorectal cancer patients. The lucky winner will be contacted by 2cureX’s clinical staff to discuss details.

The power of precision.
For every oncologist.
Today.